J. Krushinski

发表

Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.

D. Wong, F. Bymaster, E. Beedle, 2003, Bioorganic & medicinal chemistry letters.

Duloxetine (Cymbalta), a Dual Inhibitor of Serotonin and Norepinephrine Reuptake.

D. Wong, F. Bymaster, E. Beedle, 2004 .

LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake

D. Wong, F. Bymaster, J. Krushinski, 1993, Neuropsychopharmacology.

Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.

R. Fuller, J. Krushinski, D. Robertson, 1988, Journal of medicinal chemistry.

Norfluoxetine Enantiomers as Inhibitors of Serotonin Uptake in Rat Brain

D. Wong, F. Bymaster, J. Krushinski, 1993, Neuropsychopharmacology.

Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo

R. Fuller, J. Krushinski, D. Robertson, 1992, Neuropharmacology.

[3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties

J. Zgombick, J. Krushinski, D. Nelson, 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.

Characterization of type I 5α-reductase activity in DU145 human prostatic adenocarcinoma cells

N. Bruchovsky, Chung Lee, J. Krushinski, 1996, The Journal of Steroid Biochemistry and Molecular Biology.

Pharmacological characterization of the cannabinoid CB₁ receptor PET ligand ortholog, [³H]MePPEP.

T. Suter, M. Statnick, J. Krushinski, 2010, European journal of pharmacology.

Radiolabeling of a high potency cannabinoid subtype‐1 receptor ligand, N‐(4‐fluoro‐benzyl)‐4‐(3‐(piperidin‐1‐yl)‐indole‐1‐sulfonyl)benzamide (PipISB), with carbon‐11 or fluorine‐18

Sean R. Donohue, S. Hitchcock, C. Halldin, 2008 .

(R)-thionisoxetine, a potent and selective inhibitor of central and peripheral norepinephrine uptake.

J. Howbert, D. Wong, R. Fuller, 1995, Life sciences.

Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain

J. Howbert, D. Wong, R. Fuller, 1995, Neurochemistry International.

LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug.

D. Wong, F. Bymaster, J. Krushinski, 1988, Life sciences.

Synthesis of 14C‐ and 2H‐labeled 1,3‐dihydro‐3,3‐dimethyl‐5‐(1,4,5,6‐tetrahydro‐6‐oxo‐3‐pyridazinyl)‐2H‐indol‐2‐one (LY195115), an orally effective positive inotrope

J. Krushinski, D. Robertson, D. Kau, 1986 .

[3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain

J. Krushinski, D. Nelson, J. Audia, 2005, Naunyn-Schmiedeberg's Archives of Pharmacology.

Structure-activity relationships of arylimidazopyridine cardiotonics; synthesis and inotropic activity of benzthienyl- and naphthyl-substituted imidazopyridines and purines

E. Beedle, J. Krushinski, D. Robertson, 1986 .

Localization of ATP sensitive potassium channels in the rat brain using a novel radioligand, [125I]iodoglibenclamide.

J. Krushinski, D. Robertson, D. Gehlert, 1990, European journal of pharmacology.

Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2- one.

E. Beedle, J. Krushinski, D. Robertson, 1986, Journal of medicinal chemistry.

Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.

E. Beedle, J. Krushinski, D. Robertson, 1985, Journal of medicinal chemistry.

Dihydropyridazinone Cardiotonics: The Discovery and Inotropic Activity of 1,3-Dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)- 2H-indol-2-one.

E. Beedle, J. Krushinski, D. Robertson, 1987 .

Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-pyridazinyl)- 2H-indol-2-one, a potent inhibitor of cyclic AMP phosphodiesterase.

J. Krushinski, D. Robertson, N. D. Jones, 1987, Journal of medicinal chemistry.

Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.

Victor W. Pike, Christer Halldin, Amy K. Chesterfield, 2008, Journal of medicinal chemistry.

Design, synthesis and evaluation of bicyclic benzamides as novel 5-HT1F receptor agonists.

Sean R. Dinn, W. Gough, J. Krushinski, 2004, Bioorganic & medicinal chemistry letters.

SYNTHESIS OF 2-[4-METHOXY-2-[2-(METHYLSULFINYL)ETHOXY]PHENYL]-1H-IMIDAZO[4, 5-b]PYRIDINE, A POTENT NONGLYCOSIDE INHIBITOR OF Na+, K+-ATPASE

J. Krushinski, D. Robertson, 1988 .

STRUCTURE-ACTIVITY RELATIONSHIPS OF ARYLIMIDAZOPYRIDINE CARDIOTONICS: DISCOVERY AND INOTROPIC ACTIVITY OF 2-(2-METHOXY-4-(METHYLSULFINYL)PHENYL)-1H-IMIDAZO(4,5-C)PYRIDINE

E. Beedle, J. Krushinski, D. Robertson, 1985 .

Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)spiro[cycloalkane- 1,3'-[3H]indol]-2'(1'H)-ones.

J. Krushinski, D. Robertson, R. Kauffman, 1987, Journal of medicinal chemistry.

3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.

J. Howbert, P. Hipskind, S. Iyengar, 1996, Journal of medicinal chemistry.

Synthesis of a tritium-labeled indolidan analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic binding sites.

J. Krushinski, D. Robertson, R. Kauffman, 1989, Journal of medicinal chemistry.

Synthesis and Pharmacological Characterization of 2-(2,6-dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a potent, subtype selective, and orally available positive allosteric modulator of the human dopamine D1

G. Stephenson, Charles R. Yang, S. Mitchell, 2019, Journal of medicinal chemistry.

The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain

Christer Halldin, Fumihiko Yasuno, Eyassu Chernet, 2008, Neuropsychopharmacology.

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis

Todd R. Wiernicki, Charles R. Yang, T. Suter, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.

John M Schaus, D. Wong, J. Krushinski, 2007, Bioorganic & medicinal chemistry letters.

Safety and Efficiency of Intravenous Push Lacosamide Administration

G. M. Jones, J. Krushinski, Khalid Alsherbini, 2018, Neurocritical Care.

Persistent depletion of striatal dopamine and cortical norepinephrine in mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-3-pyridinol (MPTP-3-OL), an analog of MPTP.

R. Fuller, J. Krushinski, D. Robertson, 1992, Life sciences.

Preparation of 14C‐ and 18O‐labeled 2‐[2‐methoxy‐4‐(methylsulfinyl)phenyl]‐1H‐imidazo[4,5‐c]‐pyridine hydrochloride (LY175326), a cardiotonic with inotropic and vasodilator activities

J. Krushinski, D. Robertson, D. Kau, 1985 .

Expedient synthesis and biochemical properties of an [125I]-labeled analogue of glyburide, a radioligand for ATP-inhibited potassium channels.

J. Krushinski, D. Thompson, D. Gehlert, 1990, Journal of Medicinal Chemistry.

Discovery of selective N-[3-(1-methyl-piperidine-4-carbonyl)-phenyl]-benzamide-based 5-HT₁ F receptor agonists: Evolution from bicyclic to monocyclic cores.

John M Schaus, Maria-Jesus Blanco, Joseph Krushinski, 2015, Bioorganic & medicinal chemistry letters.